# Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment

> **NCT00392691** · PHASE1 · COMPLETED · sponsor: **Swiss Cancer Institute** · enrollment: 20 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** ibritumomab tiuxetan
- **DRUG:** rituximab
- **DRUG:** melphalan
- **DRUG:** vinorelbine tartrate / G-CSF
- **PROCEDURE:** autologous hematopoietic stem cell harvesting and transplantation

## Key facts

- **NCT ID:** NCT00392691
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2012-12
- **Final completion:** 2013-05
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2019-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00392691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00392691, "Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00392691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*